Publications





Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Cancer Res 2016 Sep 30;76(17):5040-53. Epub 2016 Jun 30.
Translational Oncology Program, The University of Michigan, Ann Arbor, Michigan. Department of Pediatrics, and Communicable Diseases, The University of Michigan, Ann Arbor, Michigan. Department of Pathology, The University of Michigan, Ann Arbor, Michigan.

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.
J Clin Oncol 2016 Aug 29. Epub 2016 Aug 29.
Vadim S. Koshkin, Cleveland Clinic, Cleveland, OH; Vanessa Bolejack, Cancer Research and Biostatistics, Seattle, WA; Lawrence H. Schwartz, Binsheng Zhao, Columbia University Medical Center, New York, NY; Richard L. Wahl, Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO; Rashmi Chugh, Scott M. Schuetze, Laurence H. Baker, University of Michigan Medical School; Denise K. Reinke, Sarcoma Alliance for Research Through Collaboration, Ann Arbor, MI; Joo H. O, The Catholic University of Korea; Seoul St Mary's Hospital, Seoul, Republic of Korea; and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX.








Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Nat Genet 2013 Dec 3;45(12):1446-51. Epub 2013 Nov 3.
1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA. [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA. [3].

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Clin Cancer Res 2013 Nov 17;19(21):6020-9. Epub 2013 Sep 17.
Authors' Affiliations: Dana-Farber Cancer Institute and Harvard Medical School; Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; University of Michigan, Ann Arbor, Michigan; UCLA Division of Hematology-Oncology, Santa Monica, California; Pinnacle Oncology, Scottsdale, Arizona; and Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.


A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer.
Semin Oncol 2013 Apr;40(2):135-44
Department of Radiation Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.









OF